The National Pharmaceutical Pricing Authority (NPPA) has reduced the maximum retail price of 463 non-scheduled cancer medicines.
The memorandum revising the prices downwards was issued by NPPA’s director (pricing) Amarpal Singh Sawhney on March 11.
As per the memorandum, manufacturers and hospitals have been directed to convey the revised MRP, to be effective immediately based on the trade margin formula.
The NPPA has issued the list of the 463 non-scheduled anti-cancer drugs whose prices have been drastically reduced through trade margin rationalisation.